Business and science: How risky is SynBio?

John Laurenson reports from La Défense in Paris on how Europe's biggest business district is turning vacant office space into housing. As hybrid working leaves more offices underused, cities are rethinking the future of these buildings. We compare developments in Paris with effor ...  Show more

Headspace started life as a mindfulness app. Now it's partnering with the US Navy and investing in artificial intelligence for mental health support.The company's CEO Tom Pickett speaks to us about therapy, the increasing role of technology, and tackling burnout at scale.If you'd ...  Show more

Reshma Shetty is co-founder and chief operations officer of Ginkgo Bioworks. Her problem: How do you turn cutting-edge science into a sustainable business?

Ginkgo is a synthetic biology company. The idea is to make industrial products -- fragrances, or food, or whatever ...

Professor Matthew Cobb looks at how genetic engineering became big business - from the first biotech company that produced human insulin in modified bacteria in the late 1970s to the companies like Monsanto which developed and then commercialised the first GM crops in the 1990s. ...  Show more

How to trade and invest in the biotech space with ROTY Biotech Community's Jonathan Faison (0:35). Making money in biotech (5:40). Managing sector risk (9:20). Geron - a stock he never thought he'd own (17:10).Show Notes:Finding Winners In Biotech, Probably The Riskiest SectorSyn ...  Show more

The business of life sciences came into sharp focus after the pandemic highlighted the effectiveness of mRNA vaccines in protecting people against COVID. But what exactly is life sciences and is the recent market weakness a threat to future innovation — or an opportunity? In the ...  Show more